Duodenal Mucosal Resurfacing Cuts HbA1c in T2DM

Share this content:
Duodenal Mucosal Resurfacing Cuts HbA1c in T2DM
Duodenal Mucosal Resurfacing Cuts HbA1c in T2DM

THURSDAY, Aug. 18, 2016 (HealthDay News) -- Single-procedure duodenal mucosal resurfacing (DMR) is effective for reducing glycated hemoglobin (HbA1c) in patients with type 2 diabetes, according to a study published online Aug. 12 in Diabetes Care.

Harith Rajagopalan, M.D., Ph.D., from Fractyl Laboratories Inc. in Waltham, Mass., and colleagues used novel balloon catheters to conduct DMR on varying lengths of duodenum in anesthetized patients with type 2 diabetes. Twenty-eight patients had a long duodenal segment (LS) ablated, and 11 had a short segment (SS) ablated.

The researchers found that DMR was well tolerated with minimal post-procedure gastrointestinal symptoms. Duodenal stenosis was experienced by three patients, who were treated successfully by balloon dilation. In the full cohort, HbA1c was reduced by 1.2 percent at six months (P < 0.001). The LS cohort had a more potent glycemic effect, with 2.5 percent reduction in mean HbA1c versus 1.2 percent in the SS group (P < 0.05) at three months postprocedure and 1.4 versus 0.7 percent reduction in HbA1c at six months (P = 0.3). HbA1c was reduced by 1.8 percent at six months among LS patients with a screening HbA1c of 7.5 to 10 percent and on stable antidiabetic medications postprocedure.

"Single-procedure DMR elicits a clinically significant improvement in hyperglycemia in patients with type 2 diabetes in the short-term, with acceptable safety and tolerability," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Fractyl Laboratories, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »